Literature DB >> 31838553

Diabetes and fractures: new evidence of atypical femoral fractures?

N H Rasmussen1, J Dal2, F de Vries3,4, J P van den Bergh5,6,7, M H Jensen8, P Vestergaard8.   

Abstract

Patients with diabetes have an increased risk of fractures. In this study, subtrochanteric and femoral shaft fractures were increased in patients with type 1 diabetes compared with the general population. In the light of this, more evidence points towards an association between diabetes and atypical femoral fractures.
INTRODUCTION: Patients with diabetes have an increased risk of femoral fractures, but little is known about the risk of atypical femoral fractures (AFFs). The aim of this study was to identify the risk of subtrochanteric and femoral shaft (ST/FS) fractures and estimate the risk of AFFs in patients with type 1 (T1D) and type 2 diabetes (T2D).
METHODS: From the nationwide Danish National Patient Register, we identified patients with T1D (n = 19,896), T2D (n = 312,188), and sex- and aged-matched controls without diabetes (n = 996,252) from the general population and all ST/FS fractures (n = 7509). Data were analyzed using a Cox proportional-hazards model and the incidence rate and rate ratio of ST/FS fractures were estimated.
RESULTS: The incidence rate of ST/FS fractures in T1D was 52.14 events per 100,000 person years and 73.21 per 100,000 person years in T2D. T1D was associated with an increased risk of ST/FS (HR 2.07 (95% CI 1.68-2.56)), whereas T2D was not (HR 0.99 (95% CI 0.94-1.10)). Previous ST/FS fractures were associated with an increased risk of subsequent ST/FS fractures (HR 6.95 (95% CI 6.00-8.05)) and the use of bisphosphonates with an increased risk of ST/FS fractures (HR 1.72 (95% CI 1.54-1.91)).
CONCLUSION: Patients with T1D have a higher risk of ST/FS fractures compared with sex- and age-matched controls. Since a proportion of ST/FS fractures are classified as AFFs, this could point towards the fact that AFFs also are increased in patients with T1D, but not T2D.

Entities:  

Keywords:  Atypical femoral fractures; Diabetes type 1; Diabetes type 2; Femoral shaft fracture; Fractures; Subtrochanteric fracture

Mesh:

Substances:

Year:  2019        PMID: 31838553     DOI: 10.1007/s00198-019-05224-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

1.  Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.

Authors:  Reina Armamento-Villareal; Nicola Napoli; Vinita Panwar; Deborah Novack
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

Review 2.  MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis.

Authors:  Katrine Hygum; Jakob Starup-Linde; Torben Harsløf; Peter Vestergaard; Bente L Langdahl
Journal:  Eur J Endocrinol       Date:  2017-03       Impact factor: 6.664

Review 3.  MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.

Authors:  Robert A Adler
Journal:  Eur J Endocrinol       Date:  2018-01-16       Impact factor: 6.664

4.  The Danish National Hospital Register. A valuable source of data for modern health sciences.

Authors:  T F Andersen; M Madsen; J Jørgensen; L Mellemkjoer; J H Olsen
Journal:  Dan Med Bull       Date:  1999-06

5.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

Review 6.  Type 1 diabetes and risk of fracture: meta-analysis and review of the literature.

Authors:  V N Shah; C S Shah; J K Snell-Bergeon
Journal:  Diabet Med       Date:  2015-06-12       Impact factor: 4.359

7.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

8.  Denosumab and atypical femoral fractures.

Authors:  Per Aspenberg
Journal:  Acta Orthop       Date:  2013-10-31       Impact factor: 3.717

9.  Risk of atypical femoral fracture during and after bisphosphonate use.

Authors:  Jörg Schilcher; Veronika Koeppen; Per Aspenberg; Karl Michaëlsson
Journal:  Acta Orthop       Date:  2015-01-13       Impact factor: 3.717

Review 10.  The Danish National Patient Registry: a review of content, data quality, and research potential.

Authors:  Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2015-11-17       Impact factor: 4.790

View more
  5 in total

1.  Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center.

Authors:  Noa Bareli; Roni Gat; Victoria Makarov; Ethel Siris; Merav Fraenkel; Uri Yoel
Journal:  Arch Osteoporos       Date:  2021-06-05       Impact factor: 2.617

2.  Evaluation of the Nature and Etiologies of Risk Factors for Diaphyseal Atypical Femoral Fractures.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Yuji Kasukawa; Koji Nozaka; Kimio Saito; Hayato Kinoshita; Moto Kobayashi; Norio Suzuki; Toshiaki Aizawa; Hidekazu Abe; Shigeto Maekawa; Takenori Tomite; Yuichi Ono; Kentaro Ouchi; Nobusuke Shibata; Itsuki Nagahata; Masaaki Takeshima; Manabu Akagawa; Yusuke Yuasa; Chie Sato; Yoichi Shimada
Journal:  Med Princ Pract       Date:  2021-05-31       Impact factor: 1.927

Review 3.  Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature.

Authors:  V Van Hulten; Nicklas Rasmussen; J H M Driessen; A M Burden; A Kvist; J P van den Bergh
Journal:  Curr Osteoporos Rep       Date:  2021-12-21       Impact factor: 5.096

4.  Prevalent Morphometrically Assessed Vertebral Fractures in Individuals With Type 2 Diabetes, Prediabetes and Normal Glucose Metabolism: The Maastricht Study.

Authors:  Veerle van Hulten; Cindy Sarodnik; Johanna H M Driessen; Nicolaas C Schaper; Piet P M M Geusens; Carol A B Webers; Geert-Jan Dinant; Ramon P G Ottenheijm; Nicklas H Rasmussen; Rikke Viggers; Coen D A Stehouwer; Carla J H van der Kallen; Miranda T Schram; Sandrine P G Bours; Pieter C Dagnelie; Joop P van den Bergh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-18       Impact factor: 5.555

5.  Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report.

Authors:  George F Georgiadis; Dimitrios G Begkas; Konstantinos A Maniatis; Alexandros E Vasilakis; Stamatios Theodoros D Chatzopoulos; Alexia P Balanika
Journal:  J Orthop Case Rep       Date:  2021-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.